Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02849951 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
A Phase 3 study, sponsored by Prometheus Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT02849951: Clinical Trial Phase 3 study, sponsored by Prometheus Laboratories.
NCT02849951 is a Phase 3 study that was terminated before completion, run by Prometheus Laboratories. The registered enrollment target is 25 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02849951, a Phase 3 study, was terminated before completion, sponsored by Prometheus Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
Primary Outcome
The percentage of subjects in clinical remission using the abbreviated modified Mayo score
Interventions
- DRUG LT-02
- DRUG LT-02 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-08 |
| Phase | Phase 3 |
Why NCT02849951 stopped before completion
NCT02849951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which LT-02 is the first listed.
NCT02849951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02849951 about?
NCT02849951 is a clinical study titled "A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)". The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
What is the current status of trial NCT02849951?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2016-07. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02849951?
The interventions under investigation include: LT-02 (DRUG), LT-02 Placebo (DRUG).
Who is sponsoring clinical trial NCT02849951?
This trial is sponsored by Prometheus Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02849951's enrollment target sits among peer trials
25 1941st of 2000 higher than 58 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia